Long-term miR-29b suppression reduces aneurysm formation in a Marfan mouse model

Homare Okamura1,a, Fabian Emrich1,a, Jeffrey Trojan1, Peter Chiu1, Alex R. Dalal1, Mamoru Arakawa1, Tetsuya Sato1, Kiril Penov1, Tiffany Koyano1, Albert Pedroza1, Andrew J. Connolly2, Marlene Rabinovitch3, Cristina Alvira3 & Michael P. Fischbein1

1 Department of Cardiothoracic Surgery, Stanford University, Stanford, California
2 Department of Pathology, Stanford University, Stanford, California
3 Department of Pediatrics, Stanford University, Stanford, California

Keywords
Aneurysms, aorta, Marfan syndrome, microRNA.

Abstract
Aortic root aneurysm formation and subsequent dissection and/or rupture remain the leading cause of death in patients with Marfan syndrome. Our laboratory has reported that miR-29b participates in aortic root/ascending aorta extracellular matrix remodeling during early aneurysm formation in Fbn1C1039G/+ Marfan mice. Herein, we sought to determine whether miR-29b suppression can reduce aneurysm formation long-term. Fbn1C1039G/+ Marfan mice were treated with retro-orbital LNA-anti-miR-29b inhibitor or scrambled-control-miR before aneurysms develop either (1) a single dose prenatally (pregnant Fbn1C1039G/+ mice at 14.5 days post-coitum) (n = 8–10, each group) or (2) postnatally every other week, from 2 to 22 weeks of age, and sacrificed at 24 weeks (n = 8–10, each group). To determine if miR-29b blockade was beneficial even after aneurysms develop, a third group of animals were treated every other week, starting at 8 weeks of age, until sacrificed (n = 4–6, each group). miR-29b inhibition resulted in aneurysm reduction, increased elastogenesis, decreased matrix metalloproteinase activity and decreased elastin breakdown. Prenatal LNA-anti-miR-29b inhibitor treatment decreased aneurysm formation up to age 32 weeks, whereas postnatal treatment was effective up to 16 weeks. miR-29b blockade did not slow aortic growth once aneurysms already developed. Systemic miR-29b inhibition significantly reduces aneurysm development long-term in a Marfan mouse model. Drug administration during aortic wall embryologic development appears fundamental. miR-29b suppression could be a potential therapeutic target for reducing aneurysm formation in Marfan syndrome patients.

Introduction
Patients with Marfan syndrome (MFS) typically develop aortic root aneurysms with ensuing aortic dissection remaining the leading cause of death (Judge and Dietz 2005). Over the last decade, numerous studies have demonstrated that the underlying fibrillin-1 gene mutation in MFS increases the activity of transforming growth factor-β (TGF-β) (Dietz 2010; Neptune et al. 2003). Although TGF-β blockade inhibits aneurysm formation and growth in murine models of MFS, the molecular mechanism by which excessive TGF-β signaling leads to aneurysm development remains unknown. A better understanding behind the pathophysiology of aneurysm formation will result in novel early detection methods and potentially new treatment options.

MicroRNAs (miRNA) are endogenous small single-stranded, noncoding RNA molecules that repress gene

ª2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of The Physiological Society and the American Physiological Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
expression by partial or complete complementary binding to target sequences within miRNA (Chitwood and Timmermans 2007; Mishra et al. 2009). Our laboratory has identified that the miRNA, miR-29b plays an important pathogenic role in early aneurysm development in a Marfan mouse model (Fbn1C1039G/+). MiR-29b is increased during early postnatal development exclusively in the Fbn1C1039G/+ aortic root/ascending (AS) aorta, correlating with the clinical scenario observed in MFS patients, where aneurysms typically form in the aortic root. Moreover, miR-29b suppression by anti-sense oligonucleotides prevented aneurysm development at age 4 weeks and precludes aortic wall apoptosis and extracellular matrix (ECM) remodeling (Merk et al. 2012). However, whether miR-29b blockade results in durable protection against aneurysm formation is not known.

The miR-29 family has been reported to promote ECM remodeling through its putative gene targets, including collagen, elastin, fibrillin-1, and matrix metalloproteinases (MMP) 2 and 9 (Chen et al. 2011; van Rooij et al. 2008). Interestingly, their role in aneurysm development is controversial and may depend on species, embryologic origin, location of aneurysm, and timing. Although we reported that miR-29b was overexpressed during early AS aortic aneurysm formation in a Marfan mouse model, Maegdefessel et al. found reduced miR-29b expression during abdominal aortic aneurysm (AAA) development in two murine experimental models (Maegdefessel et al. 2012; Merk et al. 2012). In addition, while in vivo administration of locked nucleic acid (LNA) anti-miR-29b (retro-orbital) reduced aneurysm formation in both animal model systems, it was associated with reduced elastin breakdown in the Marfan model system versus increased collagen deposition and fibrosis in the AAA models (Maegdefessel et al. 2012; Merk et al. 2012). In the present study, using the Fbn1C1039G/+ Marfan mouse model, we illustrate that miR-29b blockade with an oligonucleotide inhibitor slows aneurysm growth long-term. Intriguingly, a single dose of prenatal (in utero) miR-29b inhibitor is superior to a continuous postnatal regimen, suggesting that the pathogenesis of aneurysm formation in Marfan mice may be initiated during early embryologic development.

Materials and Methods

Mice

Both male and female heterozygous Fbn1C1039G/+ mice and C57BL/6j littermate wild-type (WT) controls were used. In order to inhibit miR-29b, animals were treated with either a LNA-anti-miR-29b inhibitor (mmu-miR-29b, miRCURY LNA™ microRNA Power inhibitor, Exiqon, Woburn, MA) or scrambled-control-miR using the following three different regimens:

1. **Prenatal LNA treatment.** A single retro-orbital injection was administered to pregnant Fbn1C1039G/+ mice at 14.5 days post-coitum with either (1) LNA-anti-miR-29b (5’-3′ sequences ACTGATTTCAAATGGTGCT); or (2) scrambled-control-miR (5’-3′ sequences GTGTAACAGTCTCTATACGCCCA) (miRCURY LNA microRNA inhibitor from Exiqon).

2. **Postnatal LNA treatment.** Two-week-old Fbn1C1039G/+ mice received a retro-orbital injection of (1) LNA-anti-miR-29b or (2) scrambled-control-miR every other week for 22 weeks and sacrificed at 24 weeks.

3. **Late LNA treatment.** Following aneurysm formation, we treated Fbn1C1039G/+ mice with a retro-orbital injection of (1) LNA-anti-miR-29b or (2) scrambled-control-miR at 8 weeks of age. Mice were treated every other week up to 24 weeks.

The dosage of anti-miR or scrambled miR was 4 mg/kg in all treatment groups. The optimal dose was determined with a titration curve.

All animal procedures and experiments were approved by the Administrative Panel on Laboratory Animal Care at Stanford University. All experiments were carried out in accordance with the NIH and USDA Guidelines for the Care and Use of Animals in Research.

Echocardiography

To assess AS aortic diameter, B-mode transthoracic echocardiography (TTE) was performed at 4, 8, 16, 24 and 32 weeks. Mice were sedated with 2% inhaled isoflurane (2-chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane) (Baxter Healthcare Corporation, Deerfield, IL) during the TTE procedure. The AS aortic diameter was measured in the parasternal long axis view (outer edge to outer edge) using a Vevo-770 (Visualsonics, Toronto, Canada). Mice from the prenatal LNA treatment group were sacrificed at 32 weeks. The postnatal treatment group was sacrificed at 24 weeks, the time point when aneurysm formation did not differ significantly from that of Fbn1C1039G/+ mice treated with scrambled-control-miR. Echo measurements were repeated three times and performed by two blinded investigators.

Elastin Verhoeff’s Van Gieson staining

The AS aorta was dissected and fixed in 4% paraformaldehyde. The aortic tissue was embedded in OCT Compound Histomount (Sakura, Torrance, CA) and cut into 4 μm cross sections. The slides were stained with Accustain Elastin Verhoeff’s Van Gieson (EVG) kit.
The AS aorta was harvested, embedded in OCT media without fixation and cut into 10 μm serial sections. Low-melting agarose (1%) (Sigma-Aldrich, St. Louis, MO) was dissolved in phosphate-buffered saline (PBS). Dye-quenched gelatin (DQ-gelatin) (1 mg/mL) (Invitrogen, Carlsbad, CA) was diluted 1:10 in low-melting agarose solution. Agarose solution with or without DQ-gelatin (1 mg/mL) (Invitrogen, Carlsbad, CA) was diluted 1:10 in low-melting agarose solution. Increasing concentrations (0, 20, 50, 100, 200, and 300 mmol/L) of ethylenediaminetetraacetic acid (EDTA), a pan-MMP inhibitor, was placed on the aortic specimens. We cannot exclude the possibility that EDTA cross-reacts and blocks other matrix degrading enzymes. The sections were initially placed at 4°C for 30 min to allow the agarose to solidify, then incubated at 37°C for 24 h. The specimens were then imaged using a fluorescence microscope at an excitation wavelength of 480 nm, at 50 or 200x magnification. Autofluorescence sections were imaged at an exposure time of 20 msec.

Elastase susceptibility test

The AS aorta was dissected and divided into two specimens longitudinally. Each sample was treated with PBS containing 0.5 U/mL of porcine pancreatic elastase (Invitrogen, Carlsbad, CA) for 20 min at 37°C. For controls, the elastase solution was heat-inactivated (100°C) before use. Specimens were fixed in 4% paraformaldehyde for an hour. The aortic tissues were embedded in OCT Compound Histomount (Sakura, Torrance, CA) and cut into 7 μm cross sections. The slides were mounted in glycerol on glass slides and then visualized with a Leica SP2 confocal system (Leica Microsystems, Wetzlar, Germany). Autofluorescence of elastin was excited at 488 nm, and emission was detected at 500–560 nm wavelengths. For semiquantification, the discontinuity score from 0 to 2 (0: normal, 1: 1–2 fold increase in elastic lamellar fenestration size; 2: 2–4 fold increase in elastic lamellar fenestration size) was assessed from five images in each sample by a pathologist blinded to genotype and treatment arm.

Tissue RNA extraction and quantitative polymerase chain reaction

Total RNA was isolated using TRIzol reagent (TRIzol, Invitrogen, Carlsbad, CA). RNA was quantified by Nanodrop analysis (Agilent, Foster City, CA) and samples were included when the 260/280 nm ratio was >1.6. Diluted RNA was reverse-transcribed using the TaqMan microRNA Reverse Transcription kit (Applied Biosystems, Life Technologies Carlsbad, CA) according to the manufacturer’s instructions. Subsequently, the cDNA was amplified with the Via 7 Real-time PCR system with primers (Applied Biosystems, Life Technologies Carlsbad, CA). Gene expression levels were standardized to corresponding internal controls (snR202 [mouse] for miR-29b expression and glyceraldehyde 3-phosphate dehydrogenase for other genes). Values were expressed as the fold...
change (2−ΔΔCT[microRNA]−ΔΔCT[mo2021]). All experiments included at least four replicates per group.

Statistical analysis
Statistical analysis was performed using SPSS 18.0 (SPSS Inc, Chicago, IL). Data are presented as mean ± standard error (SEM). Results are compared to age-matched, littermate WT controls or scramble control treated, if not otherwise stated.

When comparing aortic diameter growth pattern with age between treatment groups, repeated measure analysis of variance (ANOVA) was used. One-way ANOVA was utilized to determine differences between multiple treatment groups at each time point. Significance of individual differences was evaluated using the Bonferroni correction for multiple comparisons. Two-tailed Student’s t-test for parametric data was used to compare groups. A value of $P < 0.05$ was considered statistically significant.

Results
Longitudinal progression of AS aortic aneurysms in the Fbn1C1039G/+ Marfan mouse model
AS aortic diameters in Fbn1C1039G/+ and C57BL/6J WT littermate control mice were measured using TTE at 4, 8, 16, 24 and 32 weeks of age (Fig. 1). By 32 weeks, the aortic diameter in Fbn1C1039G/+ mice reached 2.14 ± 0.03 mm in comparison to 1.68 ± 0.03 mm in WT controls ($P < 0.001$).

Histological characterization with EVG staining revealed severe elastin fragmentation during aneurysm formation in Fbn1C1039G/+ mice compared to WT controls (Fig. 2A). Although we did not detect any difference in elastin breakdown at age 2 weeks (Fig. 2B), elastin fragmentation was significantly elevated in Fbn1C1039G/+ mice by 4 weeks, and persisted through 32 weeks (Fig. 2C–E).

Previously, we reported that miR-29b, a miRNA involved in ECM remodeling and apoptosis, was significantly upregulated in the Fbn1C1039G/+ AS aorta beginning at 2 weeks, peaked by 4 weeks, then returned to baseline by 8 weeks (Merk et al. 2012). Although other investigators have reported significant changes in miR-29b expression at later time points during both AS aortic and AAA development (Maegdefessel et al. 2012), no significant change in miR-29b expression was detected in the Fbn1C1039G/+ AS aorta at later time points (8–32 weeks) compared to WT (Fig. 3A).

Early blockade of miR-29b confers durable protection against aneurysm progression through 32 weeks
Although we have previously noted that aortic dilation can be prevented up to age 4 weeks in Fbn1C1039G/+ mice when treated prenatally with LNA anti-miR-29b oligonucleotide inhibitor (Merk et al. 2012), it remains unknown whether miR-29b blockade offers long-term protection against aortic aneurysm formation. Moreover, the optimal treatment strategy for aneurysm prevention is not clear. Thus, in this study, Fbn1C1039G/+ mice were treated with LNA-anti-miR-29b inhibitor or scrambled-control-miR before aneurysms developed, either (1) as a single dose administered prenatally, or (2) postnatally every other week, starting at 2 weeks of age. Then, to determine if miR-29b blockade was beneficial even after aneurysms develop, a third group of animals were treated every other week, starting at 8 weeks of age.

Both early treatment regimens with the LNA-anti-miR-29b inhibitor significantly reduced miR-29b expression levels as measured by quantitative polymerase chain reaction, compared to scrambled-control–treated groups (Fig. 3B). In the prenatal treatment group, aortic dilation in LNA-treated Fbn1C1039G/+ mice compared to the scrambled-control–treated mice was significantly reduced for up to 32 weeks, when the experiment was electively terminated (Fig. 4A). Surprisingly, continuous postnatal LNA-inhibitor treatment was less effective than the prenatal regimen (single dose), despite superior miR-29b reduction at later time points. When the treatment strategies were compared, aortic dilatation was not significantly
difference in aortic dimension between treatment and control groups (Fig. 4D). These results support our hypothesis that the molecular mechanisms that dictate late aneurysm growth are independent of miR-29b expression. Taken together, miR-29b suppression in early development is essential for long-term reduction in aneurysm formation.

**miR-29b blockade increases ECM and decreases MMP-mediated elastin breakdown**

We next aimed to define the mechanisms allowing for the superior efficacy of the prenatal miR-29b blockade to reduce aneurysm formation long-term. Correlating with a significant reduction in miR-29b expression by 1 week of life, prenatal treatment increased elastin gene expression from baseline levels that were 15.4 ± 1.7-fold lower than WT levels at 4 weeks of age ($P = 0.04$), to 2.6 ± 0.2-fold
Long-Term miR-29b Suppression Reduces Marfan Aneurysm Formation

H. Okamura et al.

Page 6

2017 | Vol. 5 | Iss. 8 | e13257

© 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of The Physiological Society and the American Physiological Society.

higher than scramble control levels \((P = 0.04)\), by 2 weeks of age \((\text{Fig. 5A and B})\). In contrast, postnatal LNA miR-29b blockade (beginning at 2 weeks of age) did not significantly increase elastin gene expression until 4 weeks of age. Of note, neither prenatal nor postnatal LNA miR-29b blockade resulted in increased elastin gene expression past 8 weeks of age \((\text{Fig. 5})\). These results suggest that LNA miR-29b blockade prevents an early impairment in elastogenesis in the \(Fbn1^{C1039G/+}\) Marfan mouse model, correlating with the normal time period when aortic elastin synthesis occurs in mice \((\text{Davis 1995})\). Furthermore, prenatal treatment may be more beneficial for aneurysm reduction due to an earlier increase in elastin gene expression.

In addition to restoring early elastogenesis, both prenatal and postnatal miR-29b blockade also decreased elastin fragmentation, although again prenatal treatment appears more beneficial long-term \((\text{Fig. 2C–E})\). Elastin degradation can be mediated by a variety of enzymes, including MMPs, serine proteinases, and cysteine proteinases \((\text{Benjamin 2001; Liu et al. 2004; Wagsater et al. 2012; Werb et al. 1982})\). We elected to focus on MMPs, given their implication in numerous other models of aortic aneurysms \((\text{Benjamin 2001; Daugherty and Cassis 2004; Ikonomidis et al. 2006; Maegdefessel et al. 2012; Merk et al. 2012})\) and since they are downstream targets of miR-29b \((\text{Chen et al. 2011})\). Of note, in situ zymography with DQ-gelatin utilized to quantify MMP activity, may also reflect other contributing proteases. To demonstrate that the elastin breakdown observed in this Marfan mouse model was due to enhanced MMP activity, non-MMP activity was measured in 4 weeks \(Fbn1^{C1039G/+}\) AS aortic wall specimens treated with EDTA, a pan-MMP inhibitor. No significant elastase activity was detected in the EDTA-treated specimens \((\text{Fig. 6A})\), suggesting that elastin fragmentation present at 4 weeks can be attributed to MMPs. Importantly, we cannot exclude the possibility that EDTA cross-reacts and blocks other matrix degrading enzymes.

Prenatal treatment with LNA anti-miR-29b decreased \(Mmp2\) gene expression in \(Fbn1^{C1039G/+}\) mice at 2 and 4 weeks, and postnatal treatment decreased \(Mmp2\) gene expression at 4 weeks. Neither treatment strategy resulted in changes in \(Mmp2\) gene expression at 8, 16, 24, or 32 weeks \((\text{Fig. 6B})\). In situ zymography with DQ gelatin was used to quantify Mmp2 and -9 activity levels \((\text{Mook et al. 2003})\). Corresponding with enhanced elastin breakdown detected in Marfan AS aortic aneurysms, \(Mmp2\) and -9 activity levels were increased in \(Fbn1^{C1039G/+}\) scrambled control mice compared to WT control at all time points, peaking by 4 weeks \((\text{Fig. 6C and D})\). Significantly reduced Mmp activity levels are measured as early as 2 weeks in the prenatal treatment group only, whereas both LNA blockade treatment strategies significantly reduced Mmp activity levels at 4 weeks, which returned to baseline by 8 weeks. The superior results detected with prenatal treatment may be beneficial due to earlier Mmp blockade.

Interestingly, although Mmp activity increased in both groups by 8 weeks, elastin breakdown remained reduced only in the prenatal treatment animals through 32 weeks \((\text{Fig. 2E})\). These data suggested that prenatal inhibition of miR-29b during early aortic wall development may confer decreased susceptibility for aortic wall elastin breakdown. To test this hypothesis, an elastin susceptibility test was
performed on aortic wall specimens from 2-week-old Fbn1<sup>C1039G/+</sup> mice treated with either (a) prenatal LNA-anti-miR-29b inhibitor, (b) prenatal scrambled-control-miR, (c) postnatal LNA-anti-miR-29b inhibitor, or (d) postnatal scrambled-control-miR. No difference in aortic wall elastin discontinuity was detected when specimens were incubated with inactivated elastase. Notably, while activated elastase increased elastin fragmentation in Fbn1<sup>C1039G/+</sup> mice treated with either postnatal treatment or scrambled control, the elastin breakdown was significantly reduced in Fbn1<sup>C1039G/+</sup> mice treated prenatally with the LNA-anti-miR-29b inhibitor (Fig. 6E).

**Increased aortic wall collagen deposition following miR-29b blockade is not protective**

miR-29b negatively regulates the gene expression of collagen types I and III, major ECM components within the aortic wall (Judge and Dietz 2005). Correlating with reduced miR-29b levels, collagens types I and III gene expression was enhanced in the prenatal group at 8 weeks (collagen type I, 1.94 ± 0.37-fold, *P* = 0.047; collagen type III, 2.85 ± 0.31-fold, *P* < 0.001), and at both 8 and 16 weeks in the postnatal group (collagen type I, 4.95 ± 1.03-fold, *P* = 0.019 and 7.23 ± 2.32-fold, *P* = 0.045, respectively; and collagen type III, 10.18 ± 1.57-fold, *P* = 0.004 and 1.69 ± 0.34-fold, *P* = 0.176, respectively) (Fig. 7A and B). Although collagen gene expression was elevated, histological staining with picrosirius red revealed that prenatal LNA anti-miR-29b inhibitor did not change aortic wall collagen deposition (prenatal: 40.7 ± 2.5 pixel intensity vs. scrambled control: 36.6 ± 0.7 pixel intensity), even though aneurysms are reduced through age 32 weeks (Fig. 7C). Interestingly, repeated postnatal doses of LNA anti-miR-29b inhibitor resulted in enhanced aortic wall collagen deposition (postnatal: 52.8 ± 3.1 pixel intensity vs. scrambled control: 40.7 ± 2.5 pixel intensity), even though aneurysms are reduced through age 32 weeks (Fig. 7C).
Long-Term miR-29b Suppression Reduces Marfan Aneurysm Formation

H. Okamura et al.

Discussion

Studies have reported that mutations within the TGF-β signaling pathway can result in a number of inheritable connective tissue disorders, including the increased systemic TGF-β observed in Marfan syndrome, the mutated TGF-β receptors seen in Loeys-Dietz syndrome, or the altered downstream TGF-β canonical signaling noted in Smad3 deficiency (Braverman 2013; Guo et al. 2006; Habashi et al. 2006; Judge and Dietz 2005; Neptune et al. 2003). While progress has been made in understanding aneurysm formation during the last decade, the molecular mechanisms downstream of TGF-β still remain unknown. For example, in Marfan syndrome, why aneurysms localize exclusively to the aortic root despite enhanced systemic TGF-β signaling is unexplained. Investigating the pathways that participate in ECM degeneration in the aortic root may lead to novel, anatomically-directed, targeted therapies to prevent or treat aneurysm formation in Marfan syndrome. In this study, using the Fbn1C1039G/+ Marfan mouse model, we illustrate that (1) miR-29b expression is only transiently increased in the AS aorta; (2) miR-29b blockade with an oligonucleotide inhibitor slows aneurysm growth long-term; (3) a single dose of prenatal miR-29b inhibitor is superior to a continuous postnatal regimen; and (4) the beneficial effects of miR-29b blockade seem most closely associated with an increase in elastin production and stability, and a decrease in Mmp activity.

The aorta is a heterogeneous structure composed of three layers, the intima, media and adventitia. Lineage studies have shown that vascular smooth muscle cells (SMC) in the different anatomic segments of the aorta have distinct embryological origins (Sinha et al. 2014). Specifically, the aortic root is derived from the second heart field (Waldo et al. 2005). The ascending aorta and arch to the ligamentum arteriosum originate from neural crest cells (Waldo et al. 2005). The descending/abdominal aortas develop from paraxial mesoderm. Recent studies have suggested that the diversity of SMC origin may explain site specific location of various vascular diseases, including atherosclerosis, aortic dissection and aneurysm development (Milewicz et al. 2008). Corroborating this theory, we found that miR-29b is increased during early postnatal development exclusively in SMC derived from the Fbn1C1039G/+ AS aorta (Merk et al. 2012), correlating with aneurysm location. miR-29b functions to regulate hundreds of genes, including those involved in SMC

Figure 5. LNA treatment increases elastin gene expression at 4 weeks. (A) Fold difference in elastin (Eln) gene expression by quantitative polymerase chain reaction (qPCR) in AS aorta of Fbn1C1039G/+ mice compared to littermate wild-type controls at E17, 0, 1, 2, 4, 8, 16, 24, 32 weeks of age (n = 4–6, each group). Results presented as mean ± SEM. *P < 0.05. **P < 0.01. (B) Fold difference in Eln gene expression by qPCR in AS aorta of Fbn1C1039G/+ prenatal anti-miR-29b LNA compared to Fbn1C1039G/+ scrambled control (Scr pre) at E17 (n = 5), 0 (n = 6), 1 (n = 7), 2 (n = 5), 4 (n = 4), 8 (n = 6), 16 (n = 3), 24 (n = 3), and 32 (n = 7) weeks of age and Fbn1C1039G/+ postnatal anti-miR-29b LNA compared to Fbn1C1039G/+ scrambled control (Scr post)-treated mice at 4 (n = 5), 8 n = 4), 16 (n = 3), and 24 (n = 5) weeks of age (n = 4–6, each group). Results presented as mean ± SEM. *P < 0.05. **P < 0.01.

col: 36.6 ± 0.7 pixel intensity, P = 0.01), yet no significant difference in aneurysm formation was noted at 24 weeks (Fig. 7D). Finally, late LNA treatment starting at 8 weeks did not increase aortic wall collagen deposition (late: 40.7 ± 3.7 pixel intensity) (Fig. 7E). Of note, picrosirius staining color changes do not reflect composition of collagen fibers (Lattouf et al. 2014).

Because LNA miR-29b blockade is administered systemically, the off-target effects were also examined. Collagen deposition and fibrosis was not increased in the heart or kidney, regardless of treatment strategy. In the postnatal treatment group only, collagen deposition was slightly increased within the liver.
Figure 6. Upregulation of Matrix Metalloproteinase (Mmp) in Fbn1\(^{C1039G/+}\) mice. (A) Elastase activity in AS aorta of 4-week-old Fbn1\(^{C1039G/+}\) mice with or without ethylenediaminetetraacetic acid (EDTA), a pan-Mmp inhibitor. Histology magnification at 50 and 200 \(\times\). (B) Fold difference in Mmp gene expression by quantitative polymerase chain reaction (qPCR) in AS aorta of Fbn1\(^{C1039G/+}\) prenatal LNA-anti-miR-29b, Fbn1\(^{C1039G/+}\) postnatal LNA-anti-miR-29b, or Fbn1\(^{C1039G/+}\) scrambled-control–treated mice at 2 (\(n = 6\) pre), 4 (\(n = 4\) pre; \(n = 4\) post), 8 (\(n = 5\) pre; \(n = 5\) post), 16 (\(n = 3\) pre; \(n = 6\) post), and 32 (\(n = 9\) pre) weeks of age. Results presented as mean ± SEM. \(\*P < 0.05\). (C) Representative in situ zymography of AS aortas of Fbn1\(^{C1039G/+}\) Scr pre, LNA pre, and LNA post at 4 and 8 weeks. (D) Mmp activity in AS aorta of Fbn1\(^{C1039G/+}\) prenatal LNA-anti-miR-29b (LNA pre) (red square), postnatal LNA-anti-miR-29b (LNA post) (green triangle), and Fbn1\(^{C1039G/+}\) prenatal scrambled control treated (Scr pre) (blue circle) at 2, 4, 8, 16, 24, and 32 weeks of age (\(n = 3\) at each time point, except \(n = 4\) at 4 weeks). Data are expressed as percentage compared with 4-week-old Fbn1\(^{C1039G/+}\) Scr pre. \(\*P < 0.05\) for LNA pre versus Scr pre, \(\#P < 0.05\) for LNA post versus Scr pre. (E) Discontinuity score of the AS aorta treated with either inactivated or activated elastase in 4-week-old Fbn1\(^{C1039G/+}\) prenatal scrambled control (Scr pre; \(n = 5\)), prenatal LNA-anti-miR-29b (LNA pre; \(n = 5\)), and postnatal LNA-anti-miR-29b (LNA post) (\(n = 10\)). The following scoring system was utilized: (0: normal, 1: 1–2 fold increase in elastic lamellar fenestration size; 2: 2–4 fold increase in elastic lamellar fenestration size). Results presented as mean ± SD *** \(P < 0.001\), ** \(P < 0.01\), * \(P < 0.05\).
Figure 7. Collagen type I and III increased by miR-29b inhibition. (A) Fold difference in ColIA1 and ColIII A1 gene expression by quantitative polymerase chain reaction (qPCR) in AS aorta (AS) of Fbn1<sup>C1039G/+</sup> prenatal LNA-anti-miR-29b (LNA pre) versus Fbn1<sup>C1039G/+</sup> scrambled control (Scr pre)-treated mice at 4 (n = 3), 8 (n = 4), 16 (n = 3), and 32 (n = 7) weeks of age. (B) Fold difference in ColIA1 and ColIII A1 gene expression by qPCR in Fbn1<sup>C1039G/+</sup> AS postnatal LNA-anti-miR-29b (LNA post) versus scrambled control (Scr post)-treated mice at 4 (n = 3), 8 (n = 5), 16 (n = 4), and 32 (n = 6) weeks of age. (C) Representative polarized light microscopy of picrosirius red staining of AS aorta in Fbn1<sup>C1039G/+</sup> prenatal LNA-anti-miR-29b (LNA pre) or scrambled control (Scr pre)-treated mice at 24 weeks of age. (D) Representative polarized light microscopy of picrosirius red staining of Fbn1<sup>C1039G/+</sup> AS aorta postnatal LNA-anti-miR-29b (LNA post) or scrambled control (Scr post)-treated mice at 24 weeks of age. (E) Representative polarized light microscopy of picrosirius red staining of Fbn1<sup>C1039G/+</sup> AS aorta late LNA-anti-miR-29b (LNA late) or scrambled control (Scr late)-treated mice at 24 weeks of age. Results presented as mean ± SEM. *P < 0.05. **P < 0.01.
apoptosis, elastogenesis, fibrillin deposition, extracellular matrix breakdown, and collagen deposition (Maegdefessel et al. 2012; Merk et al. 2012). While TGF-β appears to regulate miR-29b transcription in aortic SMC (Maegdefessel et al. 2012; Merk et al. 2012; Milewicz 2012), how TGF-β increases miR-29b expression in a manner that is temporally and spatially restricted to the AS aorta during early postnatal life, is not clear. It is possible that SMC that originate from the AS aorta respond differently to TGF-β compared to SMC from the descending aorta in this mouse model. miR-29b is regulated at the transcriptional and posttranscriptional levels (Mott et al. 2010). Putative repressors of miR-29b transcription include c-Myc, Hedgehog, Smad3, Ying-Yang1, TCF/LEF, and NF-κB (Javelaud et al. 2011; Johnson et al. 2011). We have previously shown that the negative regulators of miR-29b, c-Myc and NF-κB are reduced in the AS aorta only, leading to increased miR-29b expression (Merk et al. 2012). A more complete understanding of miR-29b transcriptional regulation in response to TGF-β may help identify why the transient, but pathologic increase in miR-29b occurs uniquely in the AS aorta of Fbn1 C1039G/+ mice, and serve to identify novel, anatomically directed therapies.

One of the key findings of this study was that a single, prenatal dose of the miR-29b inhibitor was more effective than continuous postnatal administration of the inhibitor. Thus, we aimed to define the mechanism(s) allowing for this superior reduction in aneurysm formation. Elastin is synthesized by SMC as the monomer, tropoelastin, and represents the dominant arterial wall ECM protein. Following post-translational modification, tropoelastin is deposited as alternating concentric rings of elastic lamella and SMC. Although initially thought to play mostly a structural role, there is growing evidence that elastin may be important during arterial wall morphogenesis for vascular SMC stabilization (Brooke et al. 2003). Using elastin deficient mice (Eln -/-), which are lethal due to an occlusive vascular fibrocellular pathology (Li et al. 1997), investigators have illustrated that elastin is important for SMC phenotypic modulation, proliferation and migration via G-protein coupled signaling pathways (Karnik et al. 2003; Li et al. 1998). We report here that elastin levels in the aortic media are 15-fold lower in Marfan Fbn1 C1039G/+ mice at 4 weeks than WT controls. Perhaps because of drug administration timing, only prenatal miR-29b blockade reversed this early impairment in elastogenesis, resulting in aortic media elastin levels that were 2.6-fold higher than those found in Fbn1 C1039G/+ scramble controls. In addition, both prenatal and postnatal miR-29b blockade reduce Mmp induced elastin breakdown. Interestingly, prenatal treatment resulted in more durable decreases in elastin breakdown than postnatal treatment, despite similar levels of Mmp activity by 8 weeks in both treatment groups. Although the advantage may be in part due to earlier Mmp blockade, prenatal treatment also seems to confer a developmental benefit to elastin which makes it less susceptible to elastase breakdown. Taken together, although not directly tested in this study, our data suggest that prenatal miR-29b blockade is the superior treatment strategy as it results in the stabilization of elastin levels during embryologic development, which appears to be important temporally for normal arterial wall morphogenesis. This hypothesis has obvious clinical relevance, suggesting that novel therapies directed at aneurysm prevention in Marfan syndrome may need to be initiated in utero.

The role of miR-29b in the development of abdominal aortic aneurysms has been the focus of previous studies (Milewicz 2012). Maegdefessel et al. (2012) reported that reduced miR-29b expression is a late compensatory response during AAA development in both angiotensin II treated Apoe -/- and porcine pancreatic elastase AAA mouse models, resulting in enhanced collagen deposition, fibrosis and decreased aneurysm growth. In this study, enhanced aortic wall collagen deposition in the postnatal treatment group did not render any significant protection during AS aneurysm formation. Possible mechanisms explaining this disparity include: (1) differences in the experimental model system; (2) differences in the animal age/timing of miR-29b expression; and (3) differences in aortic segment embryologic origin.

Crosas-Molist et al. (2015) detected enhanced collagen deposition in dilated human Marfan aortic specimens compared to non-dilated and healthy aortas. Whether this collagen deposition accelerates aneurysm progression or represents a beneficial response to reinforce the aortic wall hemodynamic stress remains controversial. Several studies have investigated aortic wall hemodynamic indices in Marfan syndrome, including wall compliance, wall stiffness index, and distensibility (Adams et al. 1995; Groenink et al. 1998; Savolainen et al. 1992). Baumgartner et al. (2005) found that high aortic wall distensibility was a favorable prognostic indicator, whereas reduced elasticity was predictive of aortic wall abnormalities in Marfan syndrome patients. Therefore, in our model system, the beneficial effects of continuous postnatal blockade may have been counterbalanced by the deleterious effects of reduced aortic wall elasticity (increased collagen deposition).

In conclusion, the current gap in knowledge surrounding the mechanisms leading to aortic aneurysms in Marfan syndrome has precluded the development of novel therapies to prevent aneurysm formation. This fact is highlighted by the disappointing absence of any therapeutic benefit aimed to reduce TGF-β signaling in young Marfan patients in two recent randomized clinical trials (Lacro et al. 2014; Milleron et al. 2015).
that systemic miR-29b inhibition reduces Marfan aneurysm development long-term and provides new targets for innovative preventive strategies. Slowing aneurysm growth in Marfan patients is clinically beneficial, even if simply delaying surgical intervention. Because investigators have reported that miR-29a levels were related to aortic size in human thoracic aneurysms (Jones et al. 2011), we believe miR-29 inhibition may be applicable to treating other thoracic aortic aneurysms. Intriguingly, in this animal model, drug administration during aortic wall embryologic development seems fundamental; therefore, this newly described finding may serve as the foundation that could shift our current thinking as to the optimal timing of medical intervention in order to most effectively prevent or slow aneurysm development in patients with Marfan syndrome.

Limitations

In the prenatal treatment group, Fbn1(C1039G)+/+ mice were measured up to 32 weeks, when the experiment was electively terminated. Longer follow-up would be beneficial to determine the exact efficacy of early miR-29b blockade. Importantly, because aneurysms eventually develop, miR-29b-independent events may predominate in the progression of aneurysms at later time points. In addition, although we report here that prenatal miR-29b blockade is potentially beneficial via protection of the elastin architecture during early aortic wall development in mice, we cannot rule out the potential detrimental effects during embryogenesis.

Conflict of Interest

Authors have nothing to disclose with regard to commercial support.

References

Adams, J. N., M. Brooks, T. W. Redpath, F. W. Smith, J. Dean, J. Gray, et al. 1995. Aortic distensibility and stiffness index measured by magnetic resonance imaging in patients with Marfan’s syndrome. Br. Heart J. 73:263–269.

Baumgartner, D., C. Baumgartner, G. Matyas, B. Steinmann, J. Loffler-Ragg, E. Schermer, et al. 2005. Diagnostic power of aortic elastic properties in young patients with Marfan syndrome. J. Thorac. Cardiovasc. Surg. 129:730–739.

Benjamin, I. J. 2001. Matrix metalloproteinases: from biology to therapeutic strategies in cardiovascular disease. J. Investig. Med. 49:381–397.

Braverman, A. C. 2013. Medical management of thoracic aortic aneurysm disease. J. Thorac. Cardiovasc. Surg. 145: S2–S6.

Brooke, B. S., A. Bayes-Genis, and D. Y. Li. 2003. New insights into elastin and vascular disease. Trends Cardiovasc. Med. 13:176–181.

Chen, K. C., Y. S. Wang, C. Y. Hu, W. C. Chang, Y. C. Liao, C. Y. Dai, et al. 2011. OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases. Faseb J. 25:1718–1728.

Chitwood, D. H., and M. C. Timmermans. 2007. Target mimics modulate miRNAs. Nat. Genet. 39:935–936.

Crosas-Molist, E., T. Meirelles, J. Lopez-Luque, C. Serra-Peinado, J. Selva, L. Caja, et al. 2015. Vascular smooth muscle cell phenotypic changes in patients with Marfan syndrome. Arterioscler. Thromb. Vasc. Biol. 35:960–972.

Daugherty, A., and L. A. Cassis. 2004. Mouse models of abdominal aortic aneurysms. Arterioscler. Thromb. Vasc. Biol. 24:429–434.

Davis, E. C. 1995. Elastic lamina growth in the developing mouse aorta. J. Histochem. Cytochem. 43:1115–1123.

Dietz, H. C. 2010. TGF-beta in the pathogenesis and prevention of disease: a matter of aneurysmic proportions. J. Clin. Invest. 120:403–407.

Groenink, M., A. de Roos, B. J. Mulder, J. A. Spaan, and E. E. van der Wall. 1998. Changes in aortic distensibility and pulse wave velocity assessed with magnetic resonance imaging following beta-blocker therapy in the Marfan syndrome. Am. J. Cardiol. 82:203–208.

Guo, D. C., C. L. Papke, R. He, and D. M. Milewicz. 2006. Pathogenesis of thoracic and abdominal aortic aneurysms. Ann. N. Y. Acad. Sci. 1085:339–352.

Habashi, J. P., D. P. Judge, T. M. Holm, R. D. Cohn, B. L. Loeyes, T. K. Cooper, et al. 2006. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312:117–121.

Ilkonomidis, J. S., J. A. Jones, J. R. Barbour, R. E. Stroud, L. L. Clark, B. S. Kaplan, et al. 2006. Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome. Circulation 114(Suppl I):I365–I370.

Javelaud, D., L. van Kempen, V. I. Alexaki, E. Le Scolan, K. Luo, and A. Mauviel. 2011. Efficient TGF-beta/SMAD signaling in human melanoma cells associated with high c-SKI/SnoN expression. Mol. Cancer. 10:2.

Johnson, R. W., M. P. Nguyen, S. S. Padalecki, B. G. Grubbs, A. R. Merkel, B. O. Oyajobi, et al. 2011. TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. Cancer Res. 71:822–831.

Jones, J. A., R. E. Stroud, E. C. O’Quinn, L. E. Black, J. L. Barth, J. A. Elefteriades, et al. 2011. Selective microRNA suppression in human thoracic aneurysms: relationship of miR-29a to aortic size and proteolytic induction. Circ. Cardiovasc. Genet. 6:605–613.
Judge, D. P., and H. C. Dietz. 2005. Marfan’s syndrome. Lancet 366:1965–1976.
Karnik, S. K., B. S. Brooke, A. Bayes-Genis, L. Sorensen, J. D. Wythe, R. S. Schwartz, et al. 2003. A critical role for elastin signaling in vascular morphogenesis and disease. Development 130:411–423.
Lacro, R. V., H. C. Dietz, L. A. Sleeper, A. T. Yetman, T. J. Bradley, S. D. Colan, et al. 2014. Atenolol versus losartan in children and young adults with Marfan’s syndrome. N. Engl. J. Med. 371:2061–2071.
Lattouf, R., R. Younes, D. Lutomski, N. Naaman, G. Godeau, K. Senni, et al. 2014. Picrosirius red staining: a useful tool to appraise collagen networks in normal and pathological tissues. J. Histochem. Cytochem. 62:751–758.
Li, D. Y., A. E. Toland, B. B. Boak, D. L. Atkinson, G. J. Ensing, C. A. Morris, et al. 1998. Elastin is an essential determinant of arterial morphogenesis. Nature 393:276–280.
Liu, J., G. K. Sukhova, J. S. Sun, W. H. Xu, P. Libby, and G. P. Shi. 2004. Lysosomal cysteine proteases in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24:1359–1366.
Maegdefessel, L., J. Azuma, R. Toh, D. R. Merk, A. Deng, J. T. Chin, et al. 2012. Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development. J. Clin. Invest. 122:497–506.
Merk, D. R., J. T. Chin, B. A. Dake, L. Maegdefessel, M. O. Miller, N. Kimura, et al. 2012. miR-29b participates in early aneurysm development in Marfan syndrome. Circ. Res. 110:312–324.
Milewicz, D. M. 2012. MicroRNAs, fibrotic remodeling, and aortic aneurysms. J. Clin. Invest. 122:490–493.
Milewicz, D. M., D. C. Guo, V. Tran-Fadulu, A. L. Lafont, C. L. Papke, S. Inamoto, et al. 2008. Genetic basis of thoracic aortic aneurysms and dissections: focus on smooth muscle cell contractile dysfunction. Annu. Rev. Genomics Hum. Genet. 9:283–302.
Milleron, O., F. Arnould, J. Ropers, P. Aegerter, D. Detaint, G. Delorme, et al. 2015. Marfan Sartan: a randomized, double-blind, placebo-controlled trial. Eur. Heart J. 36:2160–2166.
Mishra, P. K., N. Tyagi, M. Kumar, and S. C. Tyagi. 2009. MicroRNAs as a therapeutic target for cardiovascular diseases. J. Cell Mol. Med. 13:778–789.
Mook, O. R., C. Van Overbeeck, E. G. Ackema, F. Van Maldegem, and W. M. Frederiks. 2003. In situ localization of gelatinolytic activity in the extracellular matrix of metastases of colon cancer in rat liver using quenched fluorogenic DQ-gelatin. J. Histochem. Cytochem. 51:821–829.
Mott, J. L., S. Kurita, S. C. Cazanave, S. F. Bronk, N. W. Werneburg, and M. E. Fernandez-Zapico. 2010. Transcriptional Suppression of mir-29b-1/mir-29a Promoter by c-Myc, Hedgehog, and NF-kappaB. J. Cell. Biochem. 110:1155–1164.
Neptune, E. R., P. A. Frischmeyer, D. E. Arking, L. Myers, T. E. Bunton, B. Gayraud, et al. 2003. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat. Genet. 33:407–411.
van Rooij, E., L. B. Sutherland, J. E. Thatcher, J. M. DiMaio, R. H. Naseem, W. S. Marshall, et al. 2008. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl Acad. Sci. USA 105:13027–13032.
Savolainen, A., P. Keto, P. Hekali, L. Nisula, I. Kaitila, M. Viitasalo, et al. 1992. Aortic distensibility in children with the Marfan syndrome. Am. J. Cardiol. 70:691–693.
Sinha, S., D. Iyer, and A. Granata. 2014. Embryonic origins of human vascular smooth muscle cells: implications for in vitro modeling and clinical application. Cell. Mol. Life Sci. 71:2271–2288.
Wagsater, D., D. Johansson, V. Fontaine, E. Vorkapic, A. Backlund, A. Razuvaev, et al. 2012. Serine protease inhibitor A3 in atherosclerosis and aneurysm disease. Int. J. Mol. Med. 30:288–294.
Waldo, K. L., M. R. Hutson, H. A. Stadt, M. Zdanowicz, J. Zdanowicz, and M. L. Kirby. 2005. Cardiac neural crest is necessary for normal addition of the myocardium to the arterial pole from the secondary heart field. Dev. Biol. 281:66–77.
Werb, Z., M. J. Banda, J. H. McKerrow, and R. A. Sandhaus. 1982. Elastases and elastin degradation. J. Invest. Dermatol. 79(Suppl 1):154s–159s.